Charles Schwab Trust Co Sells 2,064 Shares of CVS Health Co. (NYSE:CVS)

Charles Schwab Trust Co reduced its stake in CVS Health Co. (NYSE:CVS) by 22.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,056 shares of the pharmacy operator’s stock after selling 2,064 shares during the period. Charles Schwab Trust Co’s holdings in CVS Health were worth $317,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CVS. Ballentine Partners LLC increased its holdings in shares of CVS Health by 17.5% during the fourth quarter. Ballentine Partners LLC now owns 5,314 shares of the pharmacy operator’s stock valued at $239,000 after acquiring an additional 793 shares in the last quarter. LaFleur & Godfrey LLC increased its holdings in CVS Health by 49.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 4,836 shares of the pharmacy operator’s stock worth $217,000 after purchasing an additional 1,610 shares in the last quarter. AHL Investment Management Inc. raised its stake in shares of CVS Health by 1.7% in the fourth quarter. AHL Investment Management Inc. now owns 43,316 shares of the pharmacy operator’s stock worth $1,944,000 after purchasing an additional 713 shares during the last quarter. M.E. Allison & CO. Inc. purchased a new position in shares of CVS Health during the fourth quarter valued at approximately $277,000. Finally, Diversify Wealth Management LLC raised its position in CVS Health by 2.6% in the 4th quarter. Diversify Wealth Management LLC now owns 16,181 shares of the pharmacy operator’s stock valued at $777,000 after buying an additional 408 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Up 1.5 %

NYSE:CVS opened at $52.72 on Tuesday. The stock has a market cap of $66.35 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 0.79 and a beta of 0.59. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $80.75. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The company’s 50 day moving average price is $51.34 and its 200-day moving average price is $56.32.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The firm had revenue of $95.43 billion for the quarter, compared to the consensus estimate of $92.72 billion. During the same period in the prior year, the company posted $2.21 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. On average, equities research analysts forecast that CVS Health Co. will post 5.22 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Thursday, January 23rd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 5.05%. The ex-dividend date is Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Analyst Ratings Changes

Several research firms have recently issued reports on CVS. StockNews.com lowered CVS Health from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Truist Financial lowered their target price on CVS Health from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Mizuho lowered their price objective on CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. TD Cowen lifted their target price on shares of CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Finally, Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $68.71.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.